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Protein Kinase C Oxidation Contributes to
ERK Inactivation in Lupus T Cells
Gabriela J. Gorelik,1 Sushma Yarlagadda,1 and Bruce C. Richardson2
Objective. CD4 T cells from patients with active
lupus have impaired ERK pathway signaling that de-
creases DNA methyltransferase expression, resulting in
DNA demethylation, overexpression of immune genes,
and autoimmunity. The ERK pathway defect is due to
impaired phosphorylation of T505 in the protein kinase
C (PKC) activation loop. However, the mechanisms
that prevent PKC T505 phosphorylation in lupus T
cells are unknown. Others have reported that oxidative
modifications, and nitration in particular, of T cells as
well as serum proteins correlate with lupus disease
activity. We undertook this study to test our hypothesis
that nitration inactivates PKC, contributing to im-
paired ERK pathway signaling in lupus T cells.
Methods. CD4 T cells were purified from lupus
patients and controls and then stimulated with phorbol
myristate acetate (PMA). Signaling protein levels, ni-
tration, and phosphorylation were quantitated by im-
munoprecipitation and immunoblotting of T cell lysates.
Transfections were performed by electroporation.
Results. Treating CD4 T cells with peroxynitrite
nitrated PKC, preventing PKC T505 phosphorylation
and inhibiting ERK pathway signaling similar to that
observed in lupus T cells. Patients with active lupus had
higher nitrated T cell PKC levels than did controls,
which correlated directly with disease activity, and
antinitrotyrosine immunoprecipitations demonstrated
that nitrated PKC, but not unmodified PKC, was
refractory to PMA-stimulated T505 phosphorylation,
similar to PKC in peroxynitrite-treated cells.
Conclusion. Oxidative stress causes PKC nitra-
tion, which prevents its phosphorylation and contrib-
utes to the decreased ERK signaling in lupus T cells.
These results identify PKC as a link between oxidative
stress and the T cell epigenetic modifications in lupus.
Systemic lupus erythematosus (SLE) is an incom-
pletely understood chronic, relapsing autoimmune dis-
ease. Persuasive evidence indicates that genetic factors
contribute to disease development. However, a lack of
complete disease concordance in identical twins and the
relapsing nature of the disease indicate that environ-
mental factors are important as well (1). The full reper-
toire of the environmental factors, and the mecha-
nism(s) by which the environmental agents contribute to
the onset of lupus and lupus flares, remain unknown.
Our group has reported that T cell DNA demethylation
contributes to the pathogenesis of human lupus by
causing overexpression of immune genes, leading to T
cell autoreactivity and the development of lupus in
genetically predisposed hosts (2). This suggests that the
environment may trigger lupus flares by inhibiting T cell
DNA methylation. The mechanisms by which environ-
mental agents cause T cell DNA demethylation in lupus
are also unknown.
DNA methylation patterns are replicated each
time a cell divides by DNAmethyltransferase 1 (DNMT-1)
(3), whose levels are regulated in part by the ERK
signaling pathway (4–6). We reported that treating
proliferating T cells with ERK pathway inhibitors, such
as hydralazine and U0126, or with DNMT inhibitors,
such as procainamide, is sufficient to demethylate the
DNA and that the demethylated T cells are sufficient to
cause a lupus-like disease in murine models (7,8). Fur-
ther, transgenic mice with an inducible T cell ERK
pathway signaling defect develop a lupus-like disease
(9). We also reported that T cells from patients with
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active lupus have impaired ERK pathway signaling, low
DNMT-1 levels, and overexpress methylation-sensitive
genes (10), suggesting that impaired ERK pathway
signaling contributes to DNA demethylation in human
lupus. Interestingly, CD4 lupus T cells demethylate the
same genetic regulatory elements demethylated by ERK
pathway inhibitors and DNMT inhibitors (11), and the
level of lupus disease activity is directly related to the
degree of signaling impairment and DNA demethylation
(10). These studies thus suggest an important role of
impaired ERK pathway signaling in triggering lupus
flares.
More recent studies traced the lupus ERK path-
way signaling defect to impaired protein kinase C
(PKC) phosphorylation (12). PKC is a key molecule
that is phosphorylated in response to a variety of signals,
and thus activates other signaling pathways including the
ERK pathway (13–15). PKC in T cells from patients
with active lupus or in hydralazine-treated T cells is not
properly phosphorylated in response to phorbol myris-
tate acetate (PMA) or other stimuli, and the defect
correlates with the lupus ERK pathway defect. Trans-
fecting human T cells with a kinase-inactive PKC
causes decreased ERK phosphorylation, indicating that
PKC is critically required for ERK pathway activation.
Additionally, the transfected cells exhibited demethyl-
ation and overexpression of the TNFSF7 (CD70) gene,
similar to findings in lupus patients (12). However, the
mechanisms inhibiting PKC phosphorylation in lupus
T cells are unknown.
Inflammation is associated with the generation of
reactive oxygen species (ROS), and patients with active
lupus have increased levels of ROS and reactive nitro-
gen intermediates (RNIs), as well as decreased levels of
oxidant scavengers (16–18). This imbalance causes in-
creased levels of superoxide (O2
), hydrogen peroxide
(H2O2), and peroxynitrite (ONOO
), all highly reactive
metabolites that cause direct toxicity by inducing chem-
ical modifications in lipids, proteins, and DNA (19).
ONOO nitrates Tyr residues to prevent phosphoryla-
tion (20) and may thus affect signaling pathways. How-
ever, the consequences of oxidative stress on T cell
signaling are also poorly understood.
Since T cell PKC kinase activity is decreased in
patients with active lupus and active lupus is character-
ized by the generation of ROS/RNIs and oxidative
protein damage, we hypothesized that PKC may be
covalently modified by ROS/RNIs in lupus T cells,
preventing its activation. The goal of this study was to
determine if oxidative modifications produced by
ONOO contribute to impaired T cell PKC phosphor-
ylation, causing the decreased ERK pathway signaling
observed in patients with active lupus.
MATERIALS AND METHODS
Reagents. Hydralazine was purchased from VWR and
peroxynitrite from Calbiochem. All other chemicals were from
Sigma.
Antibodies. The following primary antibodies were used:
polyclonal rabbit anti–phospho-PKC (at T638/641), anti–phospho-
PKC (at T538), anti–phospho-PKC (at T505), anti–phospho-
PKC (at Y311), and anti–phospho–3-phosphoinositide–
dependent protein kinase 1 (anti–phospho–PDK-1) (at Ser241),
at 1:1,000 dilution (Cell Signaling Technology). For immuno-
precipitation, antinitrotyrosine, clone 1A6 agarose conjugate,
was used (Millipore). Rabbit polyclonal anti–active MAPK
(1:5,000) was from Promega, and anti–total PKC was from
Santa Cruz Biotechnology. Secondary antibodies included
horseradish peroxidase (HRP)–conjugated anti-rabbit IgG
(1:2,000 dilution; Cell Signaling Technology) and HRP-
conjugated anti-mouse IgG (1:4,000 dilution; Amersham).
Subjects. Sixteen lupus patients (mean age 42 years,
range 27–64 years) with active or inactive disease were re-
cruited from the outpatient rheumatology clinics and inpatient
services at the University of Michigan, and 21 healthy controls
were recruited by advertising. All lupus patients met the
American College of Rheumatology revised criteria for SLE
(21). Lupus disease activity was quantified using the SLE
Disease Activity Index (SLEDAI) (22), and the range was 4–10
(mean 6.2) for the patients with active lupus and 0–2 (mean
0.5) for the patients with inactive disease. Controls were
matched to the lupus patients for age, race, and sex. These
protocols were reviewed and approved by the University of
Michigan Institutional Review Board for Human Subject Re-
search. The demographics of the patients and the medications
they received are summarized in Table 1.
T cell isolation. Peripheral blood mononuclear cells
were isolated from healthy donors or SLE patients by Ficoll-
Hypaque density-gradient centrifugation. CD4 T cells were
then purified by negative selection using magnetic beads
(CD4 T cell isolation kit; Miltenyi Biotec) as previously
reported (12).
Table 1. Demographics, disease activity, and treatment in the SLE
patients*
SLEDAI score
Patients with active disease 6.2  2.3
Patients with inactive disease 0.5  1.0
Age, years 41.8  11.1
Female:male ratio 14:2
Medications, %
Prednisone 62
Antimalarials 62
Azathioprine 25
Mycophenolate mofetil 44
Methotrexate 0
* Except where indicated otherwise, values are the mean  SD.
SLEDAI  Systemic Lupus Erythematosus Disease Activity Index.
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T cell stimulation and protein isolation. CD4 T cells
were suspended in RPMI 1640 supplemented with 10% fetal
calf serum, 2 mM L-glutamine, and penicillin/streptomycin,
and then were left unstimulated or were stimulated with
50 ng/ml PMA for 15 minutes at 37°C. Treatment with
peroxynitrite was performed at the concentrations and times
specified in each experiment and before PMA stimulation.
Following stimulation, whole cell lysates were obtained accord-
ing to previous protocols (12), and protein content was quan-
tified using the BCA Protein Assay (Pierce).
Transient transfection. T cells from normal donors
were immediately transfected with small interfering RNA
(siRNA) or the indicated mutants using Amaxa nucleofection
technology according to previous protocols (12). After 24
hours, the cells were treated as indicated, harvested, and cell
lysates were obtained as above. Small interfering RNA protein
phosphatase 2Ac (PP-2Ac) and PP-2Ac mutants H118N and
L199P were kindly provided by Dr. G. Tsokos and used as
described by Katsiari et al (23). The mean  SD transfection
efficiency was 63  6% of the total cell number and was
verified by fluorescence microscopy of cells transfected with
the positive control vector pmaxGFP, which encodes a green
fluorescent protein (GFP) and was provided with the kit.
Immunoblot analysis. Immunoblots were performed
as previously described (12). Briefly, 20 g of whole cell pro-
tein was fractionated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), transferred to nitrocellulose
membranes (Schleicher & Schuell), and then stained with
ponceau S (Sigma) to verify equal protein loading between
lanes. After incubation with the kinase-specific antibody and
then with the secondary antibody, protein bands were visual-
ized by chemiluminescence (Amersham). The bands on x-ray
films were scanned and analyzed with ImageQuant 5.2 soft-
ware (Amersham) for quantification. Where indicated, blots
were stripped and reprobed with the corresponding antibody.
Values were normalized to -actin or the corresponding
kinase, as indicated.
Immunoprecipitation. Immunoprecipitation was per-
formed according to the manufacturer’s instructions. Briefly,
lysates from normal or lupus T cells were incubated with the
agarose-conjugated antinitrotyrosine antibody overnight at
4°C. Following centrifugation, an aliquot of the supernatant
(containing non-nitrated proteins) and the beads were resus-
pended in Laemmli sample buffer and boiled for 5 minutes.
Proteins from each fraction were then analyzed in parallel by
SDS-PAGE and immunoblot analysis.
Statistical analysis. The significance of the difference
between means was determined using Student’s t-test, regres-
sion analysis, or analysis of variance as appropriate. P values
less than or equal to 0.05 were considered significant.
RESULTS
PDK-1 does not contribute to the PKC signal-
ing defect in lupus T cells. We examined the mecha-
nisms regulating PKC phosphorylation to determine
the causes of the lower levels of phosphorylated T505 in
PKC in PMA-stimulated lupus T cells. PDK-1 controls
the phosphorylation of T505 in the PKC catalytic loop
(24). We therefore examined PDK-1 activation. PDK-1
has 5 sites that are phosphorylated (Ser25, Ser393, Ser396,
Ser410, and Ser241), but only Ser241 is located in the
activation loop and is required for PDK-1 activity (25).
PDK-1 activation was therefore studied using antibodies
to PDK-1 phospho-Ser241 and immunoblotting. There
was no significant difference in PDK-1 phosphorylation
between control and lupus T cells, although phosphory-
lation of T505 in PKC was decreased in PMA-
stimulated CD4 T cells from lupus patients with active
disease (Figure 1A). The densitometric analysis of 4
Figure 1. The molecule 3-phosphoinositide–dependent protein ki-
nase 1 (PDK-1) is not affected in lupus T cells. CD4 T cells from
healthy donors (control) or from lupus patients were left unstimulated
(cont) or stimulated with phorbol myristate acetate (PMA) for 15
minutes. Twenty micrograms of whole cell lysates was fractionated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, trans-
ferred to nitrocellulose membranes, and probed with a polyclonal
antibody against phosphorylated T505 in protein kinase C (PKC), as
described in Materials and Methods. Membranes were also stripped
and reprobed with a polyclonal antibody against phosphorylated S241
in PDK-1. PKC and PDK-1 were used as controls for the correspond-
ing total protein expression. A, Representative blot comparing phos-
phorylation of PDK-1 and PKC both in a lupus patient and in a
healthy donor. B, Results of 4 similar experiments performed in
different cell preparations from healthy donors and lupus patients.
Values are the mean  SEM.   P  0.02 versus PMA-stimulated T
cells from healthy donors.
2966 GORELIK ET AL
similar experiments confirmed no significant difference
in PDK-1 activation between lupus patients and controls
(P  0.05) (Figure 1B). Our observation that phospho–
PDK-1 is expressed at similar levels in resting and
PMA-stimulated T cells is concordant with the obser-
vation that PDK-1 is constitutively active due to auto-
phosphorylation of its activation loop (26). These results
indicate that a PDK-1 activity defect is not likely to be
causing the decreased phosphorylation of T505 in PKC
in CD4 lupus T cells.
ONOO inhibits phosphorylation of T505 in
PKC. Oxidative stress plays an important role in trig-
gering lupus flares, and others have reported that serum
protein oxidation correlates with disease activity in lupus
patients and that serum proteins are abnormally nitrated
in patients with active lupus (16,27). Since ONOO is a
potent oxidizing agent that nitrates proteins, causing
functional loss (20), we sought to determine whether
ONOO causes the PKC T505 phosphorylation defect
observed in lupus T cells. CD4 T cells from healthy
subjects were treated with increasing concentrations of
ONOO and then stimulated with PMA. Treatment
with ONOO caused a concentration-dependent de-
crease in PKC T505 phosphorylation, while PKC and
PKC activation loop phosphorylation was not apprecia-
bly affected (Figure 2A). Figure 2B shows the quantita-
tive densitometric analysis of 4 serial repeat experiments
similarly measuring the effects of ONOO on the phos-
phorylation of T505 in PKC. These results indicate that
the inhibitory effects of ONOO on PKC are isoform
specific, since phosphorylation of other isoforms was
unaffected.
Figure 2. Peroxynitrite (ONOO) decreases PKC T505 phosphorylation while increasing protein nitration in T cells. CD4 T cells from healthy
donors were left untreated (cont) or treated with 20–80 M ONOO for 15 minutes and then stimulated with PMA as indicated. Whole cell proteins
were obtained and subjected to Western blot analysis. A, Representative immunoblots showing phosphorylation at the activation loops of PKC,
PKC, and PKC using antibodies specific to the phosphorylated PKC isoforms as indicated. B, Quantitative analysis of PKC phospho-T505 in
CD4 T cells from 4 healthy donors in 4 different experiments. Values were normalized to total PKC. PMA-stimulated CD4 T cells without
ONOO treatment were assigned a value of 100%. C, Representative experiment using anti–3-nitrotyrosine antibody to probe PMA-stimulated
T cell lysates. D, Relative quantitation of 3-nitrotyrosine proteins from 4 similar experiments. Untreated cells were used as controls. Values in B and
D are the mean  SEM.   P  0.01 versus PMA-stimulated cells not treated with ONOO. See Figure 1 for other definitions.
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Since ONOO nitrates Tyr residues to form
3-nitrotyrosine (20), we confirmed the effect of ONOO
by measuring 3-nitrotyrosine protein derivative forma-
tion. CD4 T cells from a healthy donor were treated
with increasing concentrations of ONOO and then
stimulated with PMA. Proteins modified by 3-nitrotyrosine
were studied by immunoblotting. We observed a
concentration-dependent increase in 3-nitrotyrosine de-
rivative formation (Figure 2C). Figure 2D shows the
mean  SEM values from densitometric analyses from
4 similar experiments, confirming that T cell proteins
are nitrated by ONOO and that their nitration levels
correlate with the ONOO-induced inhibition of phos-
phorylation of T505 in PKC shown in Figure 2B.
We also studied the phosphorylation of Y311 in
the PKC molecule, because this amino acid is phos-
phorylated in cells undergoing oxidative stress (28,29).
Figure 3A shows a representative immunoblot compar-
ing the effects of ONOO on PMA-stimulated PKC
T505 and Y311 phosphorylation. In untreated (0 M
ONOO) CD4 T cells, PMA caused a substantial
increase in T505 phosphorylation, but had no appreciable
effect on Y311 phosphorylation. It is important to note
that phospho-Y311 was almost undetectable in resting
CD4 T cells (results not shown), similar to phospho-
T505. However, ONOO induced a concentration-
dependent increase in Y311 phosphorylation in PMA-
stimulated cells that was inversely related to T505
phosphorylation (P  0.01 for ONOO versus no
ONOO; n  4 experiments). Figure 3B clearly dem-
onstrates a different pattern of PKC phosphorylation
that is stimulus dependent. While PMA promoted phos-
phorylation on T505, Y311 was almost insensitive. In
contrast, ONOO increased Y311 phosphorylation with
a concomitant decrease in phospho-T505. The lack of
additional effects caused by NaOH excluded nonspecific
effects due to pH changes caused by the ONOO
solution (Figure 3A).
PP-2Ac does not participate in the ONOO-
induced PKC defect. ONOO increases PP-2Ac activ-
ity in some cell types (30), and PP-2Ac has the highest
specific phosphatase activity toward PKC (31). Further,
PP-2Ac expression and activity are increased in T cells
from lupus patients (23). We tested whether increased
PP-2Ac activity could be responsible for the PKC
dephosphorylation caused by ONOO. T cells from
healthy donors were transfected either with 5 g of
plasmids encoding the dominant-negative PP-2Ac mu-
tants H118N or L199P (32) or with 100 nM PP-2Ac–
specific siRNA according to Katsiari et al (23). Cells
transfected with an irrelevant siRNA were used as
control, and 2 g of the empty GFP vector was trans-
fected as an internal control for transfection efficiency in
each experiment. Twenty-four hours later, the cells were
treated with ONOO for 15 minutes followed by PMA
stimulation. In 3 serial repeat experiments, relative to
PMA-stimulated T cells (set at 100%), phosphorylation
at T505 in PKC was not increased in ONOO-treated
cells overexpressing the catalytically inactive PP-2Ac
Figure 3. Differential PKC phosphorylation induced by peroxyni-
trite (ONOO). A, Representative experiment showing the effect of
different ONOO concentrations on PKC phosphorylation. CD4
T cells were isolated from healthy controls and treated with ONOO
at the concentrations specified. Following treatment the cells were
stimulated with 50 ng/ml PMA for 15 minutes, and PMA-stimulated
cells not treated with ONOO were used as control. Protein lysates
were then subjected to electrophoresis and transferred to nitrocellu-
lose membranes, and the membranes were probed with an antibody
against phosphorylated T505 in PKC. The blot was then stripped and
reprobed with an antibody against phosphorylated Y311 in PKC.
NaOH was used as vehicle control and added to the culture for 15
minutes before PMA stimulation at the same final concentration as
in the ONOO solution. B, Differential dose-response curves of PKC
phospho-T505 and PKC phospho-Y311 following ONOO treatment.
Values are the mean  SEM of 4 independent experiments.   P 
0.04 versus cells not treated with ONOO. See Figure 1 for other
definitions.
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mutants (for H118N, mean  SEM 23.39  4.2%; for
L199P, mean  SEM 31.58  4.5%) or the siRNA
(mean  SEM 28.36  5.2%) relative to nontransfected
cells (mean SD 21.01 4.8%) (P 0.62 for nontrans-
fected cells versus transfected cells; n  3 experiments),
confirming that PP-2Ac is not causing the PKC T505
phosphorylation defect in this system.
PKC nitration correlates with decreased ERK
phosphorylation. We previously reported that PKC
T505 phosphorylation is decreased in T cells from pa-
tients with active lupus (12). The decreased PKC T505
phosphorylation correlates with decreased ERK phos-
phorylation in CD4 lupus T cells and in CD4 T cells
treated with pharmacologic PKC inhibitors or trans-
fected with PKC siRNA or with a dominant-negative
PKC. To determine whether PKC nitration also inhib-
its ERK phosphorylation, CD4 T cells from healthy
controls were treated with different concentrations of
ONOO for varying times, then stimulated with PMA.
Figure 4A shows that, as expected, PMA-stimulated
ERK phosphorylation declined with increasing ONOO
concentrations and paralleled the decrease in PKC
T505 phosphorylation. This is consistent with our previ-
ous results showing that PKC T505 phosphorylation is
upstream of ERK (12) and its impairment decreases
ERK pathway signaling. Figure 4B shows the quantifi-
cation of 4 serial repeat experiments confirming this
observation.
PKC nitration in lupus. Lupus is characterized
by increased oxidative stress (16,33,34). T cells from
patients with active lupus generate large amounts of
ROS (35), and serum proteins are nitrated in these
patients (36). We therefore hypothesized that PKC is
inactivated in T cells from patients with active lupus
through nitration, similar to ONOO-treated T cells.
To address this hypothesis, CD4 T cells from 6
lupus patients with active disease (SLEDAI score 4)
were stimulated with PMA, and nitrated proteins were
immunoprecipitated from the lysates with anti–3-
nitrotyrosine antibodies. Results were compared to sim-
ilarly treated CD4 T cells from 4 lupus patients with
inactive disease. Controls included CD4 T cells from 3
healthy subjects that were left untreated or were treated
with ONOO followed by PMA stimulation. Total
PKC and PKC phospho-T505 content were then com-
pared by immunoblotting.
Nitrated and non-nitrated PKC were analyzed
as the total PKC content in the precipitate and super-
natant, respectively. The levels of total PKC (superna-
tant plus immunoprecipitate) were similar in untreated
or ONOO-treated T cells from control donors and
lupus patients (Figures 5A and B). These results confirm
previous data showing no differences in PKC protein
expression in control donors and lupus patients (12). As
anticipated, the amount of nitrated PKC (precipitated)
was higher in T cells from patients with active lupus
relative to controls (P  0.03) and with a pattern similar
to that in ONOO-treated control T cells (Figure 5A).
In contrast, Figure 5B shows that the patterns of nitra-
tion and phosphorylation of PKC did not differ signif-
icantly in CD4 T cells from patients with inactive lupus
when compared to CD4 T cells from healthy controls.
Importantly, the level of T cell PKC nitration in lupus
Figure 4. Peroxynitrite (ONOO) decreases ERK phosphorylation.
A, CD4 T cells from normal donors were left untreated (control
[cont]) or were treated for 15 minutes with ONOO at the indicated
concentrations and then stimulated with PMA. Whole cell extracts
were fractionatedby sodiumdodecyl sulfate–polyacrylamidegel electro-
phoresis, followed by immunoblotting using an antibody against
phospho-T505 in PKC. The blot was then stripped and reprobed with
an antibody against phospho-T202/Y204 in ERK. No variation in total
PKC or ERK protein expression was observed. The blot is represen-
tative of 4 independent experiments. B, Shown is quantitative immuno-
blot analysis of 4 different experiments. PMA-stimulated cells not
treated with ONOO were assigned a value of 1. Values are the
mean  SEM.   P  0.001 versus cells not treated with ONOO.
See Figure 1 for other definitions.
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patients correlated directly with the SLEDAI scores
(Figure 5C).
However, overall T505 phosphorylation in PKC
was decreased in stimulated T cells from patients with
active lupus relative to those from healthy controls (P 
0.04) (Figure 5B), and the nitrated PKC fraction from
the patients with active lupus was almost completely
refractory to PMA-stimulated phosphorylation (mean
SEM 4  2% of nitrated PKC) (P  0.04 for patients
with active lupus versus healthy controls) (Figure 5A).
As predicted, 74% of the PKC in T cells treated with
ONOO was nitrated, but only 6% of this fraction
was phosphorylated at T505 after PMA stimulation
(Figure 5A). In contrast, non-nitrated PKC was phos-
phorylated in T cells from healthy controls and from
patients with active or inactive lupus (supernatant)
(Figure 5A). These experiments thus demonstrate more
extensive PKC nitration, and less T505 phosphoryla-
tion, in T cells from patients with active lupus relative to
those from patients with inactive lupus and healthy
controls, suggesting that T505 phosphorylation decreases
in proportion to the extent of nitration and that the
degree of nitration is directly related to the disease
activity.
Figure 5. PKC nitration in lupus T cells. CD4 T cells from 3 healthy donors (control) were left untreated or were treated with peroxynitrite
(ONOO) followed by stimulation with PMA. In parallel, CD4 T cells from 6 patients with active lupus and 4 patients with inactive lupus were
stimulated with PMA. Total lysates were immunoprecipitated, and then supernatants (spnt) and precipitates (pp) were immunoblotted with an
antibody against PKC phospho-T505. Membranes were reprobed with an antibody against total PKC. A, Quantitative densitometric analysis of total
PKC and PKC phospho-T505 in the supernatant and the precipitate using CD4 T cells from healthy donors and patients with active disease.
Values are the mean  SEM of 6 independent experiments.   P  0.01;   P  0.04; #  P  0.03. B, Nitrated PKC (total PKC content
in precipitate) and PKC phospho-T505 (phosphorylated PKC in supernatant plus precipitate) as a percentage of the total PKC (expressed in
arbitrary units) in supernatant and precipitate under each experimental condition. Values are the mean SEM of 6 experiments. P values are versus
control cells not treated with ONOO. C, Correlation between nitrated PKC levels in lupus patients and scores on the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI). The P value was determined by analysis of variance. IP  immunoprecipitation; WB Western
blotting (see Figure 1 for other definitions).
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DISCUSSION
The goal of this study was to investigate mecha-
nisms causing the PKC phosphorylation defect respon-
sible for decreased ERK pathway signaling in lupus T
cells. PKC belongs to the PKC family of related serine/
threonine kinases with active roles in growth regulation
and apoptosis. PKC isoforms contain a highly conserved
C-terminal catalytic domain. However, they are subdi-
vided into 3 subfamilies according to their N-terminal
regulatory domains. Conventional isoforms comprise
PKC, PKC, and PKC, bind diacylglycerol (DAG)/
PMA in their C1 domain, and bind anionic phospholip-
ids in a calcium-dependent manner in their C2 domain.
Novel isoforms include PKC, PKC	, PKC
, PKC, and
PKC and are activated by DAG/PMA without a cal-
cium requirement. Atypical isoforms, PKC and PKC/,
are DAG/PMA and calcium independent (37).
PKC is ubiquitously expressed among cells and
tissues and is the only isoform that can be activated by
3 different mechanisms: through Ser/Thr phosphoryla-
tion, through tyrosine phosphorylation, and by caspase
3–dependent proteolytic cleavage. These are indepen-
dent mechanisms that regulate PKC activity, substrates,
and cellular localization and play critical roles during
cell growth, differentiation, and programmed cell death
as well as the cellular response to oxidative stress (38).
Our previous work identified decreased PKC
phospho-T505 levels in stimulated lupus T cells, which
correlated with the decreased ERK pathway signaling
previously reported in lupus T cells. We also demon-
strated that PKC is upstream of ERK and that im-
paired PKC/ERK pathway signaling in T cells causes
demethylation and overexpression of methylation-
sensitive genes (12). Importantly, transgenic mice lack-
ing T cell PKC activity develop a lupus-like disease with
decreased ERK signaling, overexpression of methylation-
sensitive genes, and production of anti–double-stranded
DNA antibodies similar to those observed in lupus
patients (ref. 39 and Gorelik GJ, et al: unpublished
observations), strongly supporting the hypothesis that
defective PKC signaling is sufficient to cause lupus.
PDK-1 phosphorylates PKC at T505 in the acti-
vation loop, promoting alignment of these residues with
the catalytic pocket and controlling catalytic activity of
the enzyme (24). We demonstrated that phosphoryla-
tion of Ser241, which is required for PDK-1 kinase
activity, is not appreciably affected in lupus T cells
relative to T cells from healthy donors and under the
same assay conditions in which PKC phospho-T505
levels were decreased. This implies that another mech-
anism inhibits phosphorylation at T505 in PKC in lupus
T cells.
Chronic inflammation is associated with oxidative
stress, and a prooxidative state has been described in
patients with lupus (27,34). In this prooxidative state,
higher levels of ROS/RNIs are present and can directly
cause toxicity through posttranslational modifications of
proteins and alterations of lipids and DNA. Nitric oxide
(NO) is overproduced in lupus (40) and can combine
with O2
 to form ONOO, a highly reactive and poten-
tially pathogenic molecule. Multiple markers of protein
oxidation have been found in SLE patient sera, including
protein carbonyls, protein-bound methionine sulfoxide,
decreased levels of protein thiols (27), and increases in
protein 3-nitrotyrosines that correlate with worsening
disease status (16,33,41), indicating that protein oxida-
tion and, in particular, nitrating pathways may play an
important role in the pathogenesis of SLE (33,34,36).
However, while it is recognized that overproduction of
ROS/RNIs alters and modifies T cell signaling, their
target molecules and the intracellular mechanisms that
they affect are not well understood.
Based on these observations, we investigated
whether the defective PKC activation in lupus T cells
was caused by oxidative damage. ONOO was used as
the oxidizing agent and caused PKC nitration that
resulted in decreased phosphorylation of T505. The fact
that PKC was the only PKC isoform catalytically af-
fected indicates that the ONOO inhibitory effect is
selective and specific to PMA-stimulated PKC
phospho-T505.
PKC is not phosphorylated at the activation
loop (T505) in resting T cells, but phosphorylation in-
creases following PMA stimulation and translocation to
the cytoplasmic membrane. In our studies, oxidation
modified the phosphorylation pattern, increasing ty-
rosine phosphorylation while decreasing threonine
phosphorylation, indicating specific effects on PKC
phosphorylation regulation. This differential pattern of
PKC phosphorylation also modifies its intracellular
translocation, resulting in changes to the interaction of
PKC with downstream targets (42). Recent studies
indicate that ROS can also modulate PKC activity in
other cell types. In keratinocytes, oxidation increases
PKC tyrosine phosphorylation, resulting in reduced
enzymatic activity (43), whereas in other cells, oxidation
enhances the enzymatic activity (44) or even modifies
the enzymatic specificity (45), indicating that oxidative
modifications of PKC activity may be cell type depen-
dent and/or phosphorylated residue dependent (28).
The precise effects of oxidation on T cell PKC have not
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been explored, but it is possible that oxidation of certain
residues in the molecule causes distortions in the sec-
ondary and tertiary structure, resulting in decreased
accessibility of T505 to phosphorylation. It is also possi-
ble that the rate of dephosphorylation increases with
oxidation.
The phospho-serine/threonine phosphatases
PP-1c, PP-2Ac, and PP-2C dephosphorylate PKC,
with PP-2Ac demonstrating the highest specific activity
toward PKC (31). However, our results show that T
cells transfected with catalytically inactive PP-2Ac mu-
tants or with the corresponding siRNA did not restore
PKC phosphorylation following ONOO treatment,
suggesting that modifications of PP-2Ac activity are
unlikely to be responsible for the decreased T505 phos-
phorylation observed in oxidized PKC. This observa-
tion is consistent with a study demonstrating that even
though the messenger RNA, protein, and enzymatic
activity of the PP-2A catalytic subunit (PP-2Ac) is
increased in patients with lupus, the defect is indepen-
dent of disease activity (23), while the PKC phosphor-
ylation impairment is directly related to disease activity
(12). The present work shows that oxidation of PKC
results in a selective decrease in PKC phospho-T505
levels and directly correlates with decreased phospho-
ERK levels in T cells, consistent with our previous
results.
The consequences of an oxidative environment
on ERK activity are not clearly defined and vary de-
pending on the cell system and stimulus. Decreased
phosphorylation of ERK induced by ONOO in kidneys
of s sickle cell mice has been reported (46), and
similarly, an alteration of the cellular redox state leads
to increased MAPK phosphatase 1 expression in fibro-
blasts, resulting in ERK inactivation (47). This suggests
that additional mechanisms may contribute to the de-
creased ERK phosphorylation caused by oxidative stress
in lupus T cells.
ONOOmay alter protein structure and function
by interacting with different amino acids. By oxidating
cysteine residues (S-nitrosylation), ONOO inactivates
many enzymes involved in energetic processes in addi-
tion to protein tyrosine phosphatases that may enhance
tyrosine phosphorylation–dependent signaling (20).
ONOO also oxidizes tyrosine residues (O-nitration) to
form 3-nitrotyrosine derivatives (20). Tyrosine nitration
is considered to be a major cause of ONOO-mediated
cytotoxicity because it affects protein structure and
function that may result in the generation of antigenic
epitopes (48), changes in the catalytic activity of en-
zymes, and impaired cell signal transduction (49). Nitra-
tion is a highly selective process limited to specific
tyrosine residues on a limited number of proteins. In
general, protein nitration is associated with loss of
function (46). Others have reported an increased
amount of NO-mediated oxidation products, such as
3-nitrotyrosine proteins, due to elevated levels of
ONOO in the serum of lupus patients (41).
We found higher levels of nitrotyrosine-containing
proteins in T cells from patients with active lupus than in
T cells from patients with inactive lupus or in T cells
from healthy controls. The levels of nitrated PKC were
also greater in T cells from patients with active lupus,
and PMA-stimulated T505 phosphorylation of the ni-
trated proteins was impaired. Similar results were ob-
served in control T cells pretreated with ONOO.
Therefore, the presence of significant levels of nitrated
PKC in T cells from patients with active lupus may
explain the decrease in PKC phospho-T505 levels ob-
served in T cells from lupus patients, the consequent
decrease in ERK signaling pathway, and their correla-
tion with disease severity. Protein nitration is often
associated with pathologic states related to inflamma-
tion, but is also recognized as a normal physiologic
process (20), suggesting an explanation for the presence
of nitrated proteins in T cells from healthy donors and
patients with inactive lupus. The relatively lower level of
PKC phosphorylation that we found in normal T cells
in the nitrated fraction could be due to a lesser degree of
oxidation that normally takes place during physiologic
metabolism. However, our studies also demonstrate that
human T cell PKC is directly modified by oxidation.
The oxidation selectively decreases PMA-stimulated
PKC T505 phosphorylation and is directly related to a
decrease in ERK signaling, suggesting that higher levels
of nitration cause structural changes in PKC that make
it catalytically inactive.
Our study reveals that the impaired T cell PKC
kinase activation observed in patients with active lupus is
likely due to oxidative damage and causes the impaired
ERK pathway signaling in T cells from lupus patients.
These studies point to PKC as a link between oxidative
stress, caused by environmental agents, and the epige-
netic changes observed in lupus T cells. Other poorly
understood autoimmune diseases also result from gene–
environment interactions and involve epigenetic mech-
anisms that include not only DNA methylation, but also
histone modifications and microRNA (50). Oxidative
stress may also contribute to these disorders through
mechanisms such as altered signaling.
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